Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

Annals of Neurology

Volumn 52, Issue 3, 2002, Pages 346-350

  Simons, Mikael ^a   Schwärzler, Frank ^a   Lütjohann, Dieter ^b   Von Bergmann, Klaus ^b   Beyreuther, Konrad ^c   Dichgans, Johannes ^a   Wormstall, Henning ^a   Hartmann, Tobias ^c   Schulz, Jörg B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; SIMVASTATIN;

EID: 0036714243     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10292     Document Type: Article

References (20)

1. Cholesterol and Alzheimer's disease: Is there a link?
2. Link between heart disease, cholesterol, and Alzheimer's disease: A review
3. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation
4. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
5. Statins and the risk of dementia
6. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
7. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
8. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
9. A cholesterol lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease
10. A fluid connection: Cholesterol and Abeta
11. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
12. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxy-cholesterol from the brain into the circulation
13. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
14. Clinical implications of the biopharmaceutical properties of fluvastatin
15. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
16. Cholesterol metabolism in the brain
17. Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation
18. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain
19. Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices
20. Alzheimer's disease: Genes, proteins, and therapy